Spotlight On... Valeant's pitch to creditors includes higher interest rate, potential fees; Turkey investigates drugmaker bribery after whistleblower lobs claims at Novartis; GSK aims to increase drug access for poor countries; and more...

Valeant ($VRX) wants some leeway from its creditors--and to get it, it's shelling out. The company is offering to increase the interest rate it pays by 50 basis points if they agree to ease up and let it off the hook for potential defaults on its debt, sources told Reuters. The company first ran into default risk when specialty pharmacy-related accounting missteps worth $58 million forced it to restate earnings, holding its regulatory financial forms up past its March 15 deadline. Report | More

@FiercePharma: Keryx anemia med Auryxia trounces placebo in study aimed at big new use. More from FiercePharmaMarketing | Follow @FiercePharma

@EricPFierce: Construction begins on Novo Nordisk's first US, API plant and first outside of Denmark. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: FDA falls short on safety monitoring, delaying public communications, report says. Report | Follow @CarlyHFierce

> Following Turkish whistleblower claims that Novartis ($NVS) paid bribes to secure advantages worth $85 million, Turkey's health ministry said it has launched an investigation into an unnamed drugmaker's bribery allegations. Report

> GlaxoSmithKline ($GSK) has laid out a series of steps aimed at helping increase access to its meds for the world's poorest countries. Release

> Lundbeck's board has elected Lars Rasmussen as chairman. Report

> Merck ($MRK) will present trial data for new hep C med Zepatier at the upcoming International Liver Congress 2016. Release

> Johnson & Johnson's ($JNJ) Janssen will unveil new data for a candidate hepatitis B regimen and for prospective and approved hepatitis C regimens at the International Liver Congress 2016. Release

Medical Device News

@FierceMedDev: ICYMI: Theranos slammed again after new study points to testing flaws. Article | Follow @FierceMedDev

@EmilyWFierce: Forgot how much I liked the word "torrent" until I read this lead $VRX. More from the NYT | Follow @EmilyWFierce

> Swiss team designs robotic exoskeleton that mimics human knee stability. Report

> Qiagen to pony up $100M+ for Danish molecular diagnostics outfit Exiqon. Article

Biotech News

@FierceBiotech: Jazz Pharma's much delayed rare liver disease drug finally wins FDA approval. News | Follow @FierceBiotech

@JohnCFierce: PureTech startup sets out to develop new tech for controversial 'vaginal seeding.' Article | Follow @JohnCFierce

> Lilly's new arthritis drug beats placebo in latest successful trial. Item

> Genocea shares shoot up on promising genital herpes data. Story

> Genfit moves liver disease pill into mid-stage, hints at upcoming IPO. Article

Pharma Manufacturing News

> Anuh Pharma plant savaged in EMA report. Report

> Dr. Reddy's recalling injected drug manufactured by Gland Pharma. More

> Citing microbial growth, B. Braun issues dextrose injection recall. Story

> Catalent issues lead to CRL for OPKO. Article

> Japan's Daiichi Sankyo closing Japan plant with 150 workers. Item

CRO News

> Rho seeks 30 new hires after bumper year. More

> Snapdragon Chemistry announces extended partnership, lab space, and a new leader. News

> Alten Calsoft Labs looks to extend U.S. reach, reporting services with PVR Technologies buy. Report

> Former GSK staffers launch new Canadian CRO. Story

> Quintiles named 'best CRO in Asia' again. Article

Pharma Asia News

> AZ approval for Tagrisso in Japan a big change to NSCLC treatment options in Asia. Item

> Australian pharma firms splashed AU$43M to docs, with lunches, Vienna trips raising eyebrows. Report

> Big Pharma finds second chance for failed drugs in China. More

> GSK pumps $29M into infectious disease R&D hub in Beijing. Story

> India's local rotavirus vaccine launched to combat death linked to diarrhea. Article

And Finally... The FDA has relaxed the guidelines for taking a pill that induces abortion. More (sub. req.)

Suggested Articles

Despite a veritable graveyard of drug prospects in hard-to-treat glioblastoma, Bayer hopes underperforming Stivarga can crack the code in new trials.

Online pharmacy Valisure has criticized the FDA for what it deems as irrational standards in the levels of suspected carcinogens in the drug supply.

GSK is grouping some non-core consumer products into three portfolios for sell-offs so it can win EU antitrust clearance for its Pfizer deal.